Pipeline

Life sciences are radically improving the chances of treatment, even for diseases that have yet to find therapeutic answers. Thanks to new knowledge of biotechnology, ever-increasing computing power and the advancement of artificial intelligence, we will be able to respond to patients' needs even faster.
——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————

Clinical Pipeline

With our research and development pipeline, we target some of the highest-needing therapeutic areas.

Area and MoleculeIndication
Preclinical
Phase 1
Phase 2
Phase 3
Post-Market
Ophthalmology - NGFNeurotrophic Keratitis
Ophthalmology - NGF new formulationUndisclosed corneal indication
Ophthalmology - NGFGlaucoma
Ophthalmology - TRPLM2 inhibitorAKC (Atopic keratoconjunctivitis)
Ophthalmology - LadarixinUndisclosed indication
CNS - NGFUndisclosed indication
Respiratory - ReparixinCAP (Community Aquired Pneumonia)
Respiratory - ReparixinARDS (Acute respiratory distress syndrome )
Immunology - LadarixinType 1 Diabetes
Ophthalmology - NGF
Indication: Neurotrophic Keratitis
Project Status:
  • Preclinical:

  • Phase 1:

  • Phase 2:

  • Phase 3:

Ophthalmology - NGF new formulation
Indication: Undisclosed corneal indication
Project Status:
  • Preclinical:

  • Phase 1:

  • Phase 2:

  • Phase 3:

Ophthalmology - NGF
Indication: Glaucoma
Project Status:
  • Preclinical:

  • Phase 1:

  • Phase 2:

  • Phase 3:

Ophthalmology - TRPLM2 inhibitor
Indication: AKC (Atopic keratoconjunctivitis)
Project Status:
  • Preclinical:

  • Phase 1:

  • Phase 2:

  • Phase 3:

Ophthalmology - Ladarixin
Indication: Undisclosed indication
Project Status:
  • Preclinical:

  • Phase 1:

  • Phase 2:

  • Phase 3:

CNS - NGF
Indication: Undisclosed indication
Project Status:
  • Preclinical:

  • Phase 1:

  • Phase 2:

  • Phase 3:

Respiratory - Reparixin
Indication: CAP (Community Aquired Pneumonia)
Project Status:
  • Preclinical:

  • Phase 1:

  • Phase 2:

  • Phase 3:

Respiratory - Reparixin
Indication: ARDS (Acute respiratory distress syndrome )
Project Status:
  • Preclinical:

  • Phase 1:

  • Phase 2:

  • Phase 3:

Immunology - Ladarixin
Indication: Type 1 Diabetes
Project Status:
  • Preclinical:

  • Phase 1:

  • Phase 2:

  • Phase 3:

Latest Publications

Preclinicals Program
Sars-Cov-2
Preclinical Programs
Pain & Antiflammation
Oncology

Physiochemical Characterization of Lipidic Nanoformulations Encapsulating the Antifungal Drug Natamycin

20/04/2024
Authors: Luigi Talarico, Ilaria Clemente, Alessandro Gennari, Giulia Gabbricci, Simone Pepi, Gemma Leone, Claudia Bonechi, Claudio Rossi, Simone Luca Mattioli, Nicola Detta and Agnese Magnani
Published in:
Nanomaterials
Preclinicals Program

Enabling performance portability on the LiGen drug discovery pipeline

16/04/2024
Authors: Luigi Crisci a, Lorenzo Carpentieri, Biagio Cosenza, Gianmarco Accordi, Davide Gadioli, Emanuele Vitali, Gianluca Palermo, Andrea Rosario Beccari
Preclinicals Program

Unlocking performance portability on LUMI-G supercomputer: A virtual screening case study

08/04/2024
Authors: Gianmarco Accordi, Davide Gadioli, Gianluca Palermo, Luigi Crisci, Lorenzo Carpentieri, Biagio Cosenza, Andrea R. Beccari
Published in:
ACM Digital Library
Preclinicals Program

Marcello Allegretti,

Chief Scientific Officer